Pharsight

Drugs that contain Umeclidinium Bromide; Vilanterol Trifenatate

1. Anoro Ellipta patents expiration

ANORO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7361787 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(1 year, 2 months ago)

USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(1 year, 2 months ago)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(11 months from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(11 months from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5873360 GLAXOSMITHKLINE Inhalation device
Feb, 2016

(8 years ago)

US7776895 GLAXOSMITHKLINE Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(1 year, 8 months ago)

US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(11 months from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(1 year, 2 months from now)

US7439393

(Pediatric)

GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Nov, 2025

(1 year, 5 months from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(3 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

US8511304

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Dec, 2027

(3 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(3 years from now)

US9333310

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2028

(3 years from now)

US8113199

(Pediatric)

GLAXOSMITHKLINE Counter for use with a medicament dispenser
Apr, 2028

(3 years from now)

US8161968

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Aug, 2028

(4 years from now)

US8201556 GLAXOSMITHKLINE Medicament dispenser
Feb, 2029

(4 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(5 years from now)

US8534281

(Pediatric)

GLAXOSMITHKLINE Manifold for use in medicament dispenser
Sep, 2030

(6 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(6 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(6 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(6 years from now)

US8746242

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Mai...

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents